AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

Independent Nurse: Clinical - Respiratory - Tackling COPD exacerbations in primary care.(Corticosteroids have an important place in exacerbation management)

GP

| September 29, 2006 | COPYRIGHT 2003 Haymarket Business Publications Ltd. (Hide copyright information)Copyright

COPD exacerbations can be traumatic for patients. Dr David Lynes and Sue Cross outline options for their prevention and management.

Exacerbations are distressing and disruptive for patients with COPD,1 and are associated with a worsening prognosis. They are significant events in the natural history of the disease and severe exacerbations account for a significant portion of the total costs of caring for these patients.2

A retrospective audit of 1,400 admissions for exacerbations showed that 34 per cent of patients were re-admitted and 14 per cent had died within three months.3 Early discharge and other schemes mean that many patients who would have been hospitalised in the past are now treated at home.

Preventing exacerbations

The most common causes of acute exacerbation are bacterial or viral infection, although the cause may be unidentifiable in up to 30 per cent of cases.4 It is important to consider alternative diagnoses such as pneumothorax, pulmonary embolus, or worsening of pre-existing heart failure.

New treatments and advances in our understanding of existing pharmacotherapy mean we can reduce exacerbation rates by as much as 40 per cent.

Further gains may be possible but there is a lack of evidence to support the use of a range of combination therapies.

Long-acting bronchodilators have been shown to reduce exacerbation frequency when compared with short-acting bronchodilators or placebo. Inhaled corticosteroids can also reduce exacerbations if used in the right patients. Both are recommended for exacerbation prevention in UK guidelines (see table).

Trials have shown that inhaled corticosteroids do not affect exacerbation rates in …

Related articles from newspapers, magazines, journals, and more
DATA SHOWS SPIRIVA REDUCES EXACERBATIONS IN PATIENTS WITH COPD.
News wire article from: Asia Africa Intelligence Wire May 24, 2004 700+ words
Results from landmark study suggest that Advair 500/50 provides important...
News wire article from: Chemical Business Newsbase February 21, 2007 700+ words
COPD PATIENTS ACHIEVE BETTER LUNG FUNCTION WITH SPIRIVA AND FORMOTEROL: STUDY.
News wire article from: Asia Africa Intelligence Wire September 19, 2005 700+ words
Novartis investigational bronchodilator QAB149 improves lung function and...
News wire article from: Europe Intelligence Wire September 15, 2009 700+ words
Novartis receives approval in the European Union for Onbrez Breezhaler, a new...
News wire article from: Europe Intelligence Wire December 3, 2009 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily